Global Immune Thrombocytopenia Market by Type (Acute Immune Thrombocytopenia, and Chronic Immune Thrombocytopenia), By Treatment (Intravenous Immunoglobulins, Corticosteroids, and Thrombopoietin Receptor Agonists), By End-User (Hospitals and Clinics, Specialty Centers, and Research and Academic Institutes), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032
- Published date: Oct 2023
- Report ID: 102400
- Number of Pages: 322
- Format:
-
keyboard_arrow_up
-
-
- Pfizer Inc Company Profile
- Hoffmann-La Roche Ltd
- Mylan N.V.
- Fresenius Kabi AG
- Hikma Pharmaceuticals PLC
- Hepalink Group.
- Teva Pharmaceutical Industries Ltd. Company Profile
- Amarillo Biosciences Inc
- Bolder Bio Technology Inc.
- GENOSCO Inc.
- Hansa Biopharma
- Janssen Pharmaceuticals Inc.
- Eisai Co Ltd
- CSL Limited
- Amgen Inc.
- Kyowa Hakko Kirin Co. Ltd.
- Rigel Pharmaceuticals Inc.
- Shionogi Inc.
- Dova Pharmaceuticals
- Novartis AG Company Profile
- Jiangsu Hengrui Pharmaceutical Co. Ltd.
- Shire and Ligand Pharmaceuticals Inc.
- Other Key Players
- settingsSettings
Our Clients
- 102400
- Oct 2023
Trusted by more than 17382 organizations globally
✖
Request a Sample Report
We'll get back to you as quickly as possible
|
Single User
$6,000
$3,999
USD / per unit
save 24%
|
Multi User
$8,000
$5,999
USD / per unit
save 28%
|
Corporate User
$10,000
$6,999
USD / per unit
save 32%
|
|
|---|---|---|---|
| e-Access | |||
| Report Library Access | |||
| Data Set (Excel) | |||
| Company Profile Library Access | |||
| Interactive Dashboard | |||
| Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
| Accessibility | 1 User | 2-5 User | Unlimited |
| Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
| Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
| Buy Now ($ 3,999) | Buy Now ($ 5,999) | Buy Now ($ 6,999) |
